MR1 and bacterial infectious disease: In the development of treatment strategies, efforts should be made to design tissue‐targeted MR1 ligand drugs—optimize the stability and mucosal delivery efficiency of 5‐OP‐RU analogs and develop them as adjuvants for vaccines against multidrug‐resistant bacterial infections; at the same time, design high‐affinity MR1 antagonists to block the pathogenic activation of MAIT cells in autoimmune diseases.